Triastek Revenue, Valuation, Funding & Investors

LightForce Orthodontics makes a fully personalized, 3D-printed braces system that uses AI and digital workflows to design custom brackets for each patient's anatomy. Orthodontists use the platform for treatment planning, from intraoral scans through final prescriptions, aiming to shorten treatment timelines and reduce the number of patient visits compared with standard orthodontics. The company manufactures its brackets in the United States, including at a facility in Wilmington, Massachusetts.

Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.

Ever Supreme Bio Technology Co Ltd is a Taiwan-based company. The company is engaged in research, development, and manufacturing of new drugs related to human mesenchymal stem cells and immune cells. The company operates in two segments: Cell Preparation Business Unit and Other Operating Business. The company gained a majority of revenue from the cell preparation Business, which is engaged in the research, development, manufacture, and sales of various new drugs and cell preparations, and investments related to biotechnology and medical industry businesses.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

ispace inc is a private lunar robotic exploration company that is developing micro-robotic technology to provide a low-cost and frequent transportation service. It has developed a small lander (lunar lander) and a lunar exploration rover (lunar rover) for the purpose of providing frequent and low-cost transportation services to the moon.

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

ReCode Therapeutics is a Menlo Park, California-headquartered clinical-stage genetic medicines company developing mRNA and gene-edited therapies. Its SORT LNP platform enables extrahepatic delivery to lungs and other organs for diseases like primary ciliary dyskinesia and cystic fibrosis. ReCode advances RCT2100 into Phase II trials and partners with CRISPR pioneers for targeted corrections.

SWISSto12 is a Lausanne-headquartered manufacturer of 3D-printed millimeter-wave components like waveguides and antennas. Spun off from EPFL in 2017, it produces lightweight aluminum structures for satellite communications, 5G base stations, and radar systems. SWISSto12 supplies Thales and Airbus with additive-manufactured parts reducing weight by 40 percent compared to traditional machining.

3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Seurat Technologies is a Boston-headquartered developer of Area Printing, a high-speed 3D metal additive manufacturing process originating from Lawrence Livermore National Laboratory. Founded in 2019, it holds over 130 patents and targets mass production of metal parts for aerospace and automotive industries. Seurat's technology achieves micron-level resolution at rates competing with casting, reducing carbon emissions in manufacturing.

Vanqua Bio is a Cambridge, Massachusetts-headquartered biotech firm developing therapies for neurodegenerative diseases like Parkinson's and ALS using a platform that screens human genetics and patient-derived neurons targeting lysosomal storage disorders and innate immune activation pathways.

Mighty Buildings is a San Francisco-headquartered construction technology firm using 3D printing and robotics to manufacture modular homes. The company extrudes Light Stone Material panels onsite, assembling structures in days with superior insulation to concrete. Mighty Buildings targets single-family and ADU homes compliant with California building codes. Founded in 2017, it operates a factory in Oakland producing units for Bay Area developers.